Bio Products Laboratory

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Bio Products Laboratory sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 8 completed later-stage tilt top decile by trial count

Bio Products Laboratory: 9 sponsored US clinical trials, none currently recruiting.

Bio Products Laboratory sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 7 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Immunodeficiency With Hyper-IgM, with 1 trials.

Top-decile sponsor footprint

Bio Products Laboratory ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED

Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery

NCT03161626
COMPLETED Phase 2

Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects

NCT03264157
COMPLETED Phase 3

Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases

NCT01884311
COMPLETED Phase 3

Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases

NCT01963143
COMPLETED Phase 4

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

NCT01289847
TERMINATED Phase 3

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery

NCT01086852
COMPLETED Phase 3

A Study Investigating Treatment Factor X in People With Factor X Deficiency

NCT00930176
COMPLETED Phase 3

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00504075
COMPLETED Phase 3

Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.

NCT00278954

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 6
Phase 4 1

Therapeutic Areas

Immunodeficiency With Hyper-IgM 1
X-linked Hypogammaglobulinemia 1
Common Variable Hypogammaglobulinemia 1
Wiskott-Aldrich Syndrome 1
Primary Immunodeficiency 1
Hypogammaglobulinemia 1

How the Bio Products Laboratory archive is shaped

9 indexed studies, none listed as recruiting (0% open); 8 completed (89%).

Phase mix: 7 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Immunodeficiency With Hyper-IgM (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Bio Products Laboratory: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Bio Products Laboratory sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Bio Products Laboratory4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Bio Products Laboratory sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Bio Products Laboratory sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Bio Products Laboratory page

9 registered trials is a research-attention snapshot, not an endorsement of Bio Products Laboratory or any single study.

  • None of Bio Products Laboratory's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Immunodeficiency With Hyper-IgM is the condition Bio Products Laboratory studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Immunodeficiency With Hyper-IgM trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bio Products Laboratory pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.